David Young Ph.D., Pharm.D.
Net Worth
Last updated:
What is David Young Ph.D., Pharm.D. net worth?
The estimated net worth of Dr. David Young Ph.D., Pharm.D. is at least $249,769 as of 7 Feb 2024. He owns shares worth $16,449 as insider and has received compensation worth at least $233,320 in Processa Pharmaceuticals, Inc..
What is the salary of David Young Ph.D., Pharm.D.?
Dr. David Young Ph.D., Pharm.D. salary is $58,330 per year as Co-Founder, Chairman, Interim Chief Financial Officer & Chief Executive Officer in Processa Pharmaceuticals, Inc..
How old is David Young Ph.D., Pharm.D.?
Dr. David Young Ph.D., Pharm.D. is 72 years old, born in 1953.
What stocks does David Young Ph.D., Pharm.D. currently own?
As insider, Dr. David Young Ph.D., Pharm.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | Co-Founder, Chairman, Interim Chief Financial Officer & Chief Executive Officer | 79,387 | $0.21 | $16,449 |
What does Processa Pharmaceuticals, Inc. do?
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
David Young Ph.D., Pharm.D. insider trading
Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals key executives
Processa Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. David Young Ph.D., Pharm.D. (72) Co-Founder, Chairman, Interim Chief Financial Officer & Chief Executive Officer
- Dr. Sian E. Bigora Ph.D., Pharm.D. (65) Co-Founder & Chief Devel. Officer
- Mr. James H. Stanker (67) Chief Financial Officer
- Mr. Patrick Lin (60) Co-Founder, Chief Bus. & Strategy Officer
- Mr. Robert Michael Floyd (69) Chief Operating Officer
- Ms. Wendy J. Guy (61) Co-Founder, Chief Admin. Officer & Corporation Sec.